This website your browser does not support. Please upgrade your browser Or Use google Crome
';
Latest Announcments
Other Links
CEPI board meeting focuses on identifying disease priorities and future strategy

Rapid fire

  • Inaugurated by Dr Harsh Vardhan
  • Minister S & T & ES expresses confidence in movement against epidemics
  • Pledges all the support from the government

The Department of Biotechnology (DBT) on behalf of Government of India will be partnering in the Coalition for Epidemic Preparedness and Innovations (CEPI), a new global alliance among governments, industries, academia, philanthropy, inter-governmental institutions, the World Health Organization and civil society.

The Union Minister for Science & Technology and Earth Sciences, Dr. Harsh Vardhan addressing at the inauguration of the Second Meeting of the Interim Board of Coalition for Epidemic Preparedness and Innovations (CEPI), in New Delhi on December 15, 2016.
The Union Minister for Science & Technology and Earth Sciences, Dr. Harsh Vardhan addressing at the inauguration of the Second Meeting of the Interim Board of Coalition for Epidemic Preparedness and Innovations (CEPI), in New Delhi on December 15, 2016.

The Second Meeting of the Interim Board of CEPI at New Delhi was held on December 15-16, 2016 hosted by DBT focused on identifying disease priorities, future strategy and setting of Permanent Secretariat for CEPI.

Dr. Harsh Vardhan, Hon’ble Minister for Science & Technology and Earth Sciences inaugurated the event on December 15, 2016 at Le Meridien, New Delhi in presence of all the stakeholders of CEPI and senior officials of Departments/Ministries concerned such as Department of Biotechnology, Ministry of External Affairs, DRDO, Ministry of Health & Family Welfare, Department of Pharmaceuticals, DCGI, etc.

“I am confident that the coalition has a dream to make the world free of epidemics and the determination to succeed and hence will do so. I from the government of India pledge all the support for this movement,” said Dr Harsh Vardhan.

The Union Minister for Science & Technology and Earth Sciences, Dr. Harsh Vardhan at the inauguration of the Second Meeting of the Interim Board of Coalition for Epidemic Preparedness and Innovations (CEPI), in New Delhi on December 15, 2016.
The Union Minister for Science & Technology and Earth Sciences, Dr. Harsh Vardhan at the inauguration of the Second Meeting of the Interim Board of Coalition for Epidemic Preparedness and Innovations (CEPI), in New Delhi on December 15, 2016.

The meeting is being attended by Board members from countries in Asia, Africa, Europe, South and North America as well as civil society organizations including Médecins Sans Frontières (MSF) as well as the World Health Organization.

“Coalitions like CEPI were necessary to eradicate epidemics,” said Dr. Jeremy Farrar, Director, Wellcome Trust.

Timely vaccine development needs prioritisation of diseases, preparedness for emergency” Dr. John-Arne Rottingen, CEO, CEPI pointed out.

The structure of CEPI was laid on August 31, 2016 in London and there is an interim Board currently chaired by Prof. K. VijayRaghavan, Secretary DBT. It is the highest decision making body of CEPI, and has supreme decision-making authority for all funding, policy, and product development aspects of CEPI’s operations. The scientific input to the Board is provided by a Scientific Advisory Council (SAC) where Indian scientists are members and the joint coordinating group (JCG) is the co-ordination mechanism between CEPI and stakeholders including the vaccine companies. The CEPI aim to finance and coordinate the development of new vaccines to prevent and contain infectious disease epidemics. CEPI is currently being steered by five founding partners. They are: Department of Biotechnology, Ministry of Science & Technology, GOI; Government of Norway; Wellcome Trust; Bill & Melinda Gates Foundation; and World Economic Forum.

India’s participation in CEPI would provide the opportunity to leverage vaccine development capacities in India, access to vaccines as and when needed and protection of our population and boost our ability to have a competitive vaccine industry.